Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†
Piccart, M × Hortobagyi, G N Campone, M Pritchard, K I Lebrun, F Ito, Y Noguchi, S Perez, A Rugo, H S Deleu, I Burris, H A Provencher, L Neven, Patrick Gnant, M Shtivelband, M Wu, C Fan, J Feng, W Taran, T Baselga, J #
Kluwer Academic Publishers
Annals of Oncology vol:25 issue:12 pages:2357-62
The BOLERO-2 study previously demonstrated that adding everolimus (EVE) to exemestane (EXE) significantly improved progression-free survival (PFS) by more than twofold in patients with hormone-receptor-positive (HR(+)), HER2-negative advanced breast cancer that recurred or progressed during/after treatment with nonsteroidal aromatase inhibitors (NSAIs). The overall survival (OS) analysis is presented here.